MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Voyager Therapeutics Inc

Suletud

3.36 -0.3

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.26

Max

3.46

Põhinäitajad

By Trading Economics

Sissetulek

-25M

-34M

Müük

-18M

6.3M

P/E

Sektori keskmine

6.415

63.778

Aktsiakasum

-0.59

Kasumimarginaal

-549.331

Töötajad

172

EBITDA

-25M

-37M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+348.96% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

12. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-31M

202M

Eelmine avamishind

3.66

Eelmine sulgemishind

3.36

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Voyager Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. okt 2024, 21:31 UTC

Peamised uudised

AbbVie's Deal for Alzheimer's Antibody Raises Curtain for Roche News on Wednesday -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Voyager Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

348.96% tõus

12 kuu keskmine prognoos

Keskmine 15.13 USD  348.96%

Kõrge 30 USD

Madal 9 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Voyager Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

10

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.36 / 3.885Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.